Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Med Chem ; 62(10): 5096-5110, 2019 05 23.
Artigo em Inglês | MEDLINE | ID: mdl-31013427

RESUMO

RIP1 kinase regulates necroptosis and inflammation and may play an important role in contributing to a variety of human pathologies, including inflammatory and neurological diseases. Currently, RIP1 kinase inhibitors have advanced into early clinical trials for evaluation in inflammatory diseases such as psoriasis, rheumatoid arthritis, and ulcerative colitis and neurological diseases such as amyotrophic lateral sclerosis and Alzheimer's disease. In this paper, we report on the design of potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitors starting from a high-throughput screen and the lead-optimization of this series from a lead with minimal rat oral exposure to the identification of dihydropyrazole 77 with good pharmacokinetic profiles in multiple species. Additionally, we identified a potent murine RIP1 kinase inhibitor 76 as a valuable in vivo tool molecule suitable for evaluating the role of RIP1 kinase in chronic models of disease. DHP 76 showed efficacy in mouse models of both multiple sclerosis and human retinitis pigmentosa.


Assuntos
Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacologia , Complexo de Proteínas Formadoras de Poros Nucleares/antagonistas & inibidores , Pirazóis/síntese química , Pirazóis/farmacologia , Proteínas de Ligação a RNA/antagonistas & inibidores , Animais , Disponibilidade Biológica , Linhagem Celular , Doença Crônica , Desenho de Fármacos , Encefalomielite Autoimune Experimental/tratamento farmacológico , Inibidores Enzimáticos/farmacocinética , Haplorrinos , Ensaios de Triagem em Larga Escala , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Modelos Moleculares , Esclerose Múltipla/tratamento farmacológico , Pirazóis/farmacocinética , Ratos , Retinose Pigmentar/tratamento farmacológico , Relação Estrutura-Atividade
2.
ACS Med Chem Lett ; 4(7): 632-6, 2013 Jul 11.
Artigo em Inglês | MEDLINE | ID: mdl-24900722

RESUMO

AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel-sensing enzyme that is activated in shortage of energy and suppressed in its surfeit. AMPK activation stimulates fatty acid oxidation, enhances insulin sensitivity, alleviates hyperglycemia and hyperlipidemia, and inhibits proinflammatory changes. Thus, AMPK is a well-received therapeutic target for type 2 diabetes and other metabolic disorders. Here, we will report the discovery of pyrrolopyridone derivatives as AMPK direct activators. We will illustrate the synthesis and structure-activity relationships of the series as well as some pharmacokinetic results. Some compounds exhibited encouraging oral exposure and were evaluated in a mouse diabetic model. Compound 17 showed oral activity at 30 mg/kg on blood glucose.

3.
Bioorg Med Chem Lett ; 22(8): 2963-7, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22386529
4.
Bioorg Med Chem Lett ; 22(8): 2968-72, 2012 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-22437115

RESUMO

A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine in vivo endotoxaemia model.


Assuntos
Compostos Heterocíclicos de 4 ou mais Anéis/química , Isoxazóis/síntese química , Proteínas do Tecido Nervoso/antagonistas & inibidores , Quinolinas/síntese química , Animais , Sítios de Ligação , Cristalografia por Raios X , Cobaias , Compostos Heterocíclicos de 4 ou mais Anéis/metabolismo , Inflamação/tratamento farmacológico , Isoxazóis/química , Isoxazóis/farmacologia , Camundongos , Modelos Moleculares , Ligação Proteica/efeitos dos fármacos , Quinolinas/química , Quinolinas/farmacologia , Ratos
5.
Bioorg Med Chem ; 16(11): 6218-32, 2008 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-18467104

RESUMO

We describe the discovery of novel potent inhibitors of 2,3-oxidosqualene:lanosterol cyclase inhibitors (OSCi) from a focused pharmacophore-based screen. Optimization of the most tractable hits gave a series of compounds showing inhibition of cholesterol biosynthesis at 2mg/kg in the rat with distinct pharmacokinetic profiles. Two compounds were selected for toxicological study in the rat for 21 days in order to test the hypothesis that low systemic exposure could be used as a strategy to avoid the ocular side effects previously described with OSCi. We demonstrate that for this series of inhibitors, a reduction of systemic exposure is not sufficient to circumvent cataract liabilities.


Assuntos
Catarata/enzimologia , Dislipidemias/enzimologia , Inibidores Enzimáticos/síntese química , Inibidores Enzimáticos/farmacocinética , Olho/efeitos dos fármacos , Transferases Intramoleculares/antagonistas & inibidores , Animais , Anticolesterolemiantes/efeitos adversos , Anticolesterolemiantes/síntese química , Anticolesterolemiantes/farmacocinética , Catarata/induzido quimicamente , Catarata/tratamento farmacológico , Linhagem Celular Tumoral , Dislipidemias/induzido quimicamente , Inibidores Enzimáticos/efeitos adversos , Olho/metabolismo , Feminino , Humanos , Fígado/efeitos dos fármacos , Fígado/metabolismo , Masculino , Oxazóis/farmacocinética , Oxazóis/uso terapêutico , Piperazinas/efeitos adversos , Piperazinas/síntese química , Piperazinas/farmacocinética , Piperidinas/farmacocinética , Piperidinas/uso terapêutico , Ratos , Ratos Sprague-Dawley
6.
J Med Chem ; 50(4): 685-95, 2007 Feb 22.
Artigo em Inglês | MEDLINE | ID: mdl-17243659

RESUMO

The peroxisome proliferator activated receptors PPARalpha, PPARgamma, and PPARdelta are ligand-activated transcription factors that play a key role in lipid homeostasis. The fibrates raise circulating levels of high-density lipoprotein cholesterol and lower levels of triglycerides in part through their activity as PPARalpha agonists; however, the low potency and restricted selectivity of the fibrates may limit their efficacy, and it would be desirable to develop more potent and selective PPARalpha agonists. Modification of the selective PPARdelta agonist 1 (GW501516) so as to incorporate the 2-aryl-2-methylpropionic acid group of the fibrates led to a marked shift in potency and selectivity toward PPARalpha agonism. Optimization of the series gave 25a, which shows EC50 = 4 nM on PPARalpha and at least 500-fold selectivity versus PPARdelta and PPARgamma. Compound 25a (GW590735) has been progressed to clinical trials for the treatment of diseases of lipid imbalance.


Assuntos
HDL-Colesterol/sangue , PPAR alfa/agonistas , Propionatos/síntese química , Tiazóis/síntese química , Animais , Apolipoproteína A-I/genética , VLDL-Colesterol/sangue , Cristalografia por Raios X , Cães , Dislipidemias/sangue , Dislipidemias/tratamento farmacológico , Humanos , Ligantes , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Modelos Moleculares , PPAR alfa/química , Propionatos/farmacocinética , Propionatos/farmacologia , Estrutura Terciária de Proteína , Ratos , Ratos Wistar , Relação Estrutura-Atividade , Tiazóis/farmacocinética , Tiazóis/farmacologia , Triglicerídeos/sangue
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA